Concordant HIV infection and visceral leishmaniasis in Ethiopia: The influence of antiretroviral treatment and other factors on outcome

Clinical Infectious Diseases

Volumn 46, Issue 11, 2008, Pages 1702-1709

  Ter Horst, Rachel ^a   Collin, Simon M ^b,d   Ritmeijer, Koert ^a   Bogale, Adey ^a   Davidson, Robert N ^c  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c NORTHWICK PARK HOSPITAL   (United Kingdom)

^d Canynge Hall ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; MILTEFOSINE; RIFAMPICIN; STAVUDINE; STIBOGLUCONATE SODIUM;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; ETHIOPIA; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; TUBERCULOSIS; VISCERAL LEISHMANIASIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTI-HIV AGENTS; ANTIGENS, CD4; ANTIPROTOZOAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; ETHIOPIA; HIV INFECTIONS; HUMANS; LEISHMANIASIS, VISCERAL; TREATMENT OUTCOME;

EID: 43949118839     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/587899     Document Type: Article

References (36)

1. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001; 95:239-43.
2. Guerin PJ, Olliaro P, Sundar S, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002; 2:494-501.
3. Pintado V, Martin-Rabadan P, Rivera ML, Moreno S, Bouza E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients: a comparative study. Medicine (Baltimore) 2001; 80:54-73.
4. Kubar J, Marty P, Lelievre A, et al. Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection: impact of the CD4+ T-lymphocyte counts. AIDS 1998; 12:2147-53.
5. Paredes R, Munoz J, Diaz I, Domingo P, Gurgui M, Clotet B. Leishmaniasis in HIV infection. J Postgrad Med 2003; 49:39-49.
6. Wolday D, Akuffo H, Demissie A, Britton S. Role of Leishmania donovani and its lipophosphoglycan in CD4+ T-cell activation-induced human immunodeficiency virus replication. Infect Immun 1999; 67:5258-64.
7. Cruz I, Nieto J, Moreno J, Canavate C, Desjeux P, Alvar J. Leishmania/HIV co-infections in the second decade. Indian J Med Res 2006; 123:357-88.
8. Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 2003; 97(Suppl 1):3-15.
9. Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997; 10:298-319.
10. Laguna F, Lopez-Velez R, Pulido F, et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS 1999;13:1063-9.
11. Pasquau F, Ena J, Sanchez R, et al. Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region. Eur J Clin Microbiol Infect Dis 2005; 24:411-8.
12. Pintado V, Lopez-Velez R. HIV-associated visceral leishmaniasis. Clin Microbiol Infect 2001; 7:291-300.
13. Russo R, Laguna F, Lopez-Velez R, et al. Visceral leishmaniasis in those infected with HIV: clinical aspects and other opportunistic infections. Ann Trop Med Parasitol 2003; 97(Suppl 1):99-105.
14. Lopez-Velez R. The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are coinfected with HIV. Ann Trop Med Parasitol 2003; 97(Suppl 1):143-7.
15. Fernández Cotarelo MJ, Abellan Martínez J, Guerra Vales JM, Martínez Sánchez P, Rodrigo Gómez de la Bárcena M, Salto Fernández E. Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis 2003; 37:973-7.
16. World Health Organization (WHO). Leishmania/HIV co-infection in southwestern Europe 1990-1998: retrospective analysis of 965 cases. Report WHO/LEISH/2000.42. Geneva: WHO, 2000.
17. Berman J. Visceral leishmaniasis in the New World and Africa. Indian J Med Res 2006; 123:289-94.
18. Rabello A, Orsini M, Disch J. Leishmania/HIV co-infection in Brazil: an appraisal. Ann Trop Med Parasitol 2003; 97(Suppl 1):17-28.
19. Ritmeijer K, Veeken H, Melaku Y, et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV coinfected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001; 95:668-72.
20. Lyons S, Veeken H, Long J. Visceral leishmaniasis and HIV in Tigray, Ethiopia. Trop Med Int Health 2003; 8:733-9.
21. Ritmeijer K, Dejenie A, Assefa Y, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 2006; 43:357-64.
22. Wolday D, Berhe N, Akuffo H, Desjeux P, Britton S. Emerging Leishmania/HIV co-infection in Africa. Med Microbiol Immunol 2001; 190:65-7.
23. Haile T, Anderson SD. Visceral leishmaniasis in northern Ethiopia. East Afr Med J 2006; 83:389-92.
24. Mira JA, Corzo JE, Rivero A, et al. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am J Trop Med Hyg 2004; 70:298-301.
25. UNAIDS/WHO Working Group on Global HIV/AIDS/STI Surveillance. Guidelines for using HIV testing technologies in surveillance. Report WHO/CDC/CSR/EDC/2001. 16. Geneva: World Health Organization, 2001.
26. World Health Organization (WHO). Manual on visceral leishmaniasis. Report WHO/Leish/96.40. Geneva: WHO, 1996.
27. Meredith SE, Kroon NC, Sondorp E, et al. Leish-KIT, a stable direct agglutination test based on freeze-dried antigen for serodiagnosis of visceral leishmaniasis. J Clin Microbiol 1995; 33:1742-5.
28. Casado JL, Lopez-Velez R, Pintado V, Quereda C, Antela A, Moreno S. Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. Eur J Clin Microbiol Infect Dis 2001; 20:202-5.
29. Soriano V, Dona C, Rodriguez-Rosado R, Barreiro P, Gonzalez-Lahoz J. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2000; 14:383-6.
30. Berenguer J, Cosin J, Miralles P, Lopez JC, Padilla B. Discontinuation of secondary anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS 2000; 14:2946-8.
31. Lopez-Velez R, Videla S, Marquez M, et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004; 53:540-3.
32. Ribera E, Ocaña I, de Otero J, Cortes E, Gasser I, Pahissa A. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med 1996; 100:496-501.
33. Perez-Molina JA, Lopez-Velez R, Montilla P, Guerrero A. Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients. AIDS 1996; 10:237-8.
34. Yeung KT, Chan M, Chan CK. The safety of i.v. pentamidine administered in an ambulatory setting. Chest 1996; 110:136-40.
35. Lawn SD, Wilkinson RJ. Immune reconstitution disease associated with parasitic infections following antiretroviral treatment. Parasite Immunol 2006; 28:625-33.
36. Barat C, Zhao C, Ouellette M, Tremblay MJ. HIV-1 replication is stimulated by sodium stibogluconate, the therapeutic mainstay in the treatment of leishmaniasis. J Infect Dis 2007; 195:236-45.